Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Lancet Oncol. 2017 Dec 12;19(1):65–75. doi: 10.1016/S1470-2045(17)30909-9

Figure 1. Study Flow Diagram.

Figure 1

Data reported in this publication are for patients who had received ibrutinib as the last B-cell receptor pathway inhibitor (BCRi) therapy prior to enrollment (43 from the main cohort and 48 from the expansion cohort). *Data from patients who received idelalisib as their last BCRi prior to enrollment (n=36) will be reported in a separate publication and are indicated by the grey boxes in the diagram.